{"id":"W4413791504","doi":"10.1016/s2152-2650(25)01391-6","title":"POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Lymphoma; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160937,0.0005891069,0.000769961,0.0002462821,0.0002752384,0.0007496757,0.0005165339,0.0007989941,0.01446068],"category_scores_gemma":[0.0004350376,0.0002183828,0.0007196434,0.0001497187,0.0003844082,0.0004074913,0.0003297457,0.002072874,0.002137484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000517233,"about_ca_system_score_gemma":0.0006227167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009626609,"about_ca_topic_score_gemma":0.00201241,"domain_scores_codex":[0.9998546,0.00005616645,0.000005142548,0.00002544029,0.00001475821,0.00004388881],"domain_scores_gemma":[0.9997817,0.00004410071,0.00001870232,0.00001145182,0.00001384999,0.0001302949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3871946,0.01589057,0.009235288,0.001511838,0.001986302,0.0008013649,0.0003469106,0.002858276,0.04539655,0.001339082,0.05914218,0.4742971],"study_design_scores_gemma":[0.3451926,0.4237872,0.05892983,0.000462006,0.002489147,0.001925203,0.0002777959,0.003367417,0.01880144,0.001102405,0.1435534,0.0001115822],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9257836,0.02849476,0.001190493,0.007986988,0.001897925,0.001095538,0.003640936,0.0005708571,0.02933881],"genre_scores_gemma":[0.9660221,0.007911217,0.001458513,0.003011087,0.0007150588,0.0004225011,0.003079115,0.0001002145,0.0172803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01446068,"threshold_uncertainty_score":0.04837579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02393427790860347,"score_gpt":0.3349150465922123,"score_spread":0.3109807686836088,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}